$SBFM

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it launched generic amoxicillin in Canada and began shipping to pharmacies this week in multiple dosages and strengths. The company cited 2025 global amoxicillin sales of about $4.9B, projected to reach about $6.4B by 2031. It also noted its Canadian portfolio includes 60 drugs on market.

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval to market its 2mg generic Dienogest tablets for first-line treatment of endometriosis-related pelvic pain. Distribution will be handled by its wholly owned Canadian subsidiary, Nora Pharma. The company expects retail pharmacy shipments by end-2026. Shares rose 6.84% premarket to $1.25.

Sunshine Biopharma Inc. (NASDAQ:SBFM) said it received Canadian regulatory approval for its 2mg generic Dienogest tablets for first-line treatment of pelvic pain from endometriosis. Distribution will be through its wholly owned Nora Pharma. Management expects retail shipments by end-2026. The article also notes a June one-for-ten reverse split and recent approval for generic ondansetron.

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 sunshine_ex1001.htm AT-THE-MARKET ISSUANCE SALES AGREEMENT, Exhibit 10.1 AT-THE-MARKET ISSUANCE SALES AGREEMENT July 20, 2026 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sunshine Biopharma Inc., a Colorado corpora

Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 sunshine_ex1001.htm RELEASE AGREEMENT Exhibit 10.1 AGREEMENT OF TRANSACTION AND MUTUAL RELEASE Between: Malek Chamoun , domiciled at XXXXXXXXXX (hereinafter “ Chamoun ”) And: Sunshine Biopharma inc ., having a place of business at 1565 Lionel-Boulet boulevard, Varennes,

Sunshine Biopharma Inc. (SBFM) shares rose about 66% pre-market on June 2, 2026, after a 1-for-10 reverse stock split took effect June 1. The company also said Health Canada approved its generic rivaroxaban tablets (2.5mg, 10mg, 15mg, 20mg), with pharmacy shipments expected to start in October 2026 via Nora Pharma.

Sunshine Biopharma (NASDAQ:SBFM) shares fell 5.17% to $0.30 in after-hours trading after the company announced a one-for-ten reverse stock split effective at the market open June 1, 2026. The firm said the move is to regain Nasdaq’s minimum bid-price compliance and expects shares outstanding to drop from 21.24 million to about 2.12 million.

Sunshine Biopharma Inc. (SBFM) has announced that an SEC filing, Form EFFECT, has become effective as of May 18, 2026, at 11:00 A.M. This filing is related to an S-1 registration statement (File Number: 333-295800). The company's stock overview, recent news, and SEC filings are also highlighted.

Shares of Sunshine Biopharma Inc. ( NASDAQ:SBFM ) are trading higher Thursday after the Florida-based pharmaceutical company announced the launch of a generic prescription drug. What To Know: Sunshine Biopharma, through its wholly owned Canadian subsidiary Nora Pharma, announced the launch of ...